Literature DB >> 27623625

Accessorized DPI: a Shortcut towards Flexibility and Patient Adaptability in Dry Powder Inhalation.

Francesca Buttini1,2, James Hannon3, Kristi Saavedra3, Irene Rossi1, Anna Giulia Balducci1,4, Hugh Smyth3,5, Andy Clark3,6, Paolo Colombo7.   

Abstract

PURPOSE: In this work, a novel powder dispersion add-on device, the AOS (Axial Oscillating Sphere), was studied in conjunction with commercially available DPI devices to improve the powder dispersion.
METHODS: An ordered mixture of formoterol fumarate and lactose was selected. We studied in two laboratories located at different altitudes the dispensing and dispersion of the drug at different flow rates, paying particular attention to a number of metrics of Fine Particle Dose (FPD).
RESULTS: Two novel findings emerged from the data collected. First, the aerosol quality, measured as fine particle dose, can be increased by adding the accessory promoting the dispersion and de-aggregation of the formulation. The second finding was that, albeit the emitted dose was independent of altitude, the drug/lactose carrier DPI aerosolizing performance changed with the altitude of testing. In particular, fine particle dose depended on both altitude and device configuration. The RS01 inhaler without the AOS accessory used at higher altitude gave the lowest FPD values. By combining the AOS accessory with the DPI, however, the performance dependence on altitude/atmospheric pressure was essentially removed.
CONCLUSIONS: Increasing inhaler performance can be achieved using an add-on accessory that enhances aerosol dispersion and minimizes flow rate dependency.

Entities:  

Keywords:  atmospheric pressure; axial oscillating sphere; dry powder inhaler; fine particle dose; formoterol fumarate

Mesh:

Substances:

Year:  2016        PMID: 27623625     DOI: 10.1007/s11095-016-2023-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

Review 1.  Aerosol drug delivery: developments in device design and clinical use.

Authors:  Myrna B Dolovich; Rajiv Dhand
Journal:  Lancet       Date:  2010-10-29       Impact factor: 79.321

Review 2.  In vitro/in vivo comparisons in pulmonary drug delivery.

Authors:  Stephen P Newman; Hak-Kim Chan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2008-03       Impact factor: 2.849

3.  Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children.

Authors:  K G Nielsen; I L Auk; K Bojsen; M Ifversen; B Klug; H Bisgaard
Journal:  Eur Respir J       Date:  1998-02       Impact factor: 16.671

4.  The effect of altitude on inhaler performance.

Authors:  Jordan T F Titosky; Chelsea M D Morin; Jonathan D Suderman; Jason S Olfert; Warren H Finlay; Reinhard Vehring
Journal:  J Pharm Sci       Date:  2014-06-02       Impact factor: 3.534

5.  Inhaled therapy in elderly COPD patients; time for re-evaluation?

Authors:  Sheba Jarvis; Philip W Ind; Robert J Shiner
Journal:  Age Ageing       Date:  2007-01-31       Impact factor: 10.668

6.  Validation of a RP-HPLC method for the assay of formoterol and its related substances in formoterol fumarate dihydrate drug substance.

Authors:  Samuel O Akapo; Muhammad Asif
Journal:  J Pharm Biomed Anal       Date:  2003-12-04       Impact factor: 3.935

7.  Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.

Authors:  L Pekka Malmberg; Paula Rytilä; Pertti Happonen; Tari Haahtela
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

8.  Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.

Authors:  Wilfried De Backer; Annick Devolder; Gianluigi Poli; Daniela Acerbi; Raffaella Monno; Christiane Herpich; Knut Sommerer; Thomas Meyer; Fabrizia Mariotti
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-06       Impact factor: 2.849

Review 9.  NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma.

Authors:  Massimo Corradi; Henry Chrystyn; Borja G Cosio; Michal Pirozynski; Stelios Loukides; Renaud Louis; Monica Spinola; Omar S Usmani
Journal:  Expert Opin Drug Deliv       Date:  2014-06-12       Impact factor: 6.648

10.  Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations.

Authors:  Nicola Scichilone; Mario Spatafora; Salvatore Battaglia; Rita Arrigo; Alida Benfante; Vincenzo Bellia
Journal:  J Asthma Allergy       Date:  2013-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.